Portfolio by Sector
Healthcare and Biotech
Health Dialog is a leading provider of care management, healthcare analytics, and decision support. The firm is a private, wholly owned subsidiary of Bupa, a global health and care company of more than $10 billion in revenues headquartered in London, England. Health Dialog provides population analytics, interactive decision aids, and healthcare decision programs to over 20 million people around the world.
Idera Pharmaceuticals (NASDAQ:IDRA) develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants.
Our proprietary drug candidates are designed to modulate specific Toll-like Receptors (TLRs), which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for our internal development programs and our partnered programs, and generates opportunities for additional collaborative alliances.
The Immune Response Corporation
The Immune Response Corporation (OTC Bulletin Board: IMRP, formerly IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and REMUNE(R) and IR103 for the treatment of HIV infection. These therapies are in Phase II clinical development and are designed to stimulate disease pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax(TM), REMUNE(R) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.
ImThera Medical is developing a novel, neurostimulation medical device for the treatment of Obstructive Sleep Apnea (OSA). Through its Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy involving targeted tongue-muscle stimulation, ImThera’s open-loop hypoglossal nerve multi-contact device delivers muscle tone to key tongue muscles during sleep, opening the upper airway and substantially reducing or eliminating OSA events.
Medisync Bioservices Inc. offers product development, clinical trial management, and data management services for the pharmaceutical, biotechnology and medical device industries. The company was founded in 2006 and is based in Delray Beach, Florida. Acquired in 2011 by Vyteris Inc.
Minrad International, Inc.
Minrad International is an acute care medical device and pharmaceutical firm. Its pharmaceutical line produces inhalation anesthetics including enflurane, isoflurane and sevoflurane. The medical device products incorporate patented real time image guidance technologies which enable medical professionals to improve the accuracy of minimally invasive interventional procedures while reducing radiation exposure for both patients and medical staff. Acquired in 2009 by Piramal Healthcare Limited
Myriad Genetics, Inc. (NASDAQ:MYGN) is a molecular diagnostic company based in Salt Lake City, Utah. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new molecular diagnostic products that assess an individual’s risk for developing disease later in life (predictive medicine), identify a patient’s likelihood of responding to a particular drug therapy and tailor a patient’s drug dose to ensure optimal treatment (personalized medicine), and assess a patient’s risk of disease progression and disease recurrence (prognostic medicine).
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is a leading stem cell company focused on developing and marketing products to treat medical conditions in the inflammatory, autoimmune, orthopedic and cardiovascular areas. Osiris’ stem cell products have significant therapeutic potential because of their ability to regulate inflammation, promote tissue regeneration and prevent pathological scar formation.
Prescient Medical, Inc. is a privately-held medical device company founded to commercialize pioneering products for the prevention of heart attacks. Prescient is developing new diagnostic techniques and treatments to address the physiology of the full spectrum of coronary plaques and its product development portfolio includes both diagnostic and therapeutic catheter-based devices that will allow interventional cardiologists to more precisely tailor focal treatment according to the unique needs of each patient.
Prolor Biotech, Inc. (AMEX: PBTH) is a clinical stage biopharmaceutical company applying unique technologies, including its patented CTP (Carboxyl Terminal Peptide) a short amino acid sequence that occurs naturally in humans) technology, primarily to develop longer-acting, proprietary versions of already approved therapeutic proteins.
Prospect owns and operates five community-based hospitals in the greater Los Angeles area, and manages the provision of healthcare services to HMO enrollees in southern California, through its network of specialist and primary care physicians. Prospect merged in 2010 with Leonard Green & Partners, L.P., a private equity fund.
Stolle Milk Biologics, Inc. (SMBI), a worldwide leader in wellness-enhancing products derived from milk-based technology and the foremost innovator in milk science. Through extensive clinical trials conducted over the past four decades, SMBI milk products have been scientifically documented to assist in strengthening the body's immune function as well as helping to complement anti-inflammatory response and promote enhanced athletic performance.
TechRx is the industry’s largest provider of pharmacy software solutions that automates order processing for high-volume pharmacies. TechRx was acquired by NDCHealth in 2003 and is now part of McKesson.
WaferGen Biosystems, Inc. (OTC:WGBSE) is a leader in the development, manufacture and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries.